Form 4: Amylyx Pharmaceuticals Chief Legal Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 1,540 shares of common stock on March 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On March 5, 2024, Gina Mazzariello, the Chief Legal Officer of Amylyx Pharmaceuticals, sold 1,540 shares of the company's common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at a weighted average price of $18.7279, with individual transactions ranging from $18.62 to $18.82.
- Following the transaction, Mazzariello directly owns 81,372 shares of Amylyx Pharmaceuticals.
- The sale was automatic and not at the discretion of the reporting person.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes. It doesn't indicate any significant positive or negative sentiment regarding the company's prospects.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This transaction appears to be a standard sale to cover tax obligations, which is a common practice.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of the stock sale transaction. |
| 03/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.